Skip to main content

Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).

Publication ,  Conference
Strickler, JH; Rushing, CN; Uronis, HE; Morse, M; Blobe, GC; Zafar, Y; Hsu, SD; Arrowood, C; Haley, S; Dropkin, E; Niedzwiecki, D; Hurwitz, H
Published in: Journal of Clinical Oncology
May 20, 2016

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

3548 / 3548

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Strickler, J. H., Rushing, C. N., Uronis, H. E., Morse, M., Blobe, G. C., Zafar, Y., … Hurwitz, H. (2016). Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC). In Journal of Clinical Oncology (Vol. 34, pp. 3548–3548). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.3548
Strickler, John H., Christel N. Rushing, Hope Elizabeth Uronis, Michael Morse, Gerard C. Blobe, Yousuf Zafar, Shiaowen David Hsu, et al. “Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 34:3548–3548. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3548.
Strickler JH, Rushing CN, Uronis HE, Morse M, Blobe GC, Zafar Y, et al. Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3548–3548.
Strickler, John H., et al. “Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 3548–3548. Crossref, doi:10.1200/jco.2016.34.15_suppl.3548.
Strickler JH, Rushing CN, Uronis HE, Morse M, Blobe GC, Zafar Y, Hsu SD, Arrowood C, Haley S, Dropkin E, Niedzwiecki D, Hurwitz H. Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3548–3548.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

3548 / 3548

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences